|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Robbins Geller Rudman & Dowd LLP today announced that a class action has been commenced on behalf of holders of Albany Molecular Research, Inc. stockholders as of July 10, 2017.
Complaint Alleges Tortious Interference of Scientific Research on Important Opioid-Deterrent Technology WESTFIELD, N.J. , Sept. 12, 2017 /PRNewswire/ -- 3ST Research LLC, a company focused on the discovery, ...
ALBANY, N.Y. , Aug. 31, 2017 /PRNewswire/ -- Albany Molecular Research, Inc. (NASDAQ: AMRI), a global contract research, development and manufacturing organization working with the life sciences industry ...